Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone"

Trial Profile

Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone"

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Deferiprone (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms FAIR-PARK-II
  • Most Recent Events

    • 21 Apr 2016 Status changed from not yet recruiting to recruiting.
    • 27 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top